Se Hwan Yang, Ph.D. - Chief Executive Officer
Dr. Se Hwan Yang founded NeoImmuneTech in January 2014. Dr. Yang has created several intellectual-property protected inventions, including the hyFc® platform technology and drug candidate. Prior to his position at NIT, Dr. Yang was Genexine’s Head of Research Institute and Business division from 2007 to 2014 and has served as a BOD member of Genexine. He received his Ph.D. from Pohang University of Science and Technology and has over 20 years of experiences of research, product development and business in life sciences, including molecular biology, immunology and protein engineering.
Luke Oh Ph.D. - President
Dr. Luke Oh is the president of NeoImmuneTech, who oversees all research, manufacturing, clinical development, and approvals.
Dr. Oh has a Ph.D. in Neuroimmunology from the McGill University (Montreal, Canada), and he has held various roles in research and development for leading organizations such as Mallinckrodt Pharmaceuticals, Human Genome Sciences, and Vertex Pharmaceuticals. Also Dr. Oh is an expert in regulatory policies and drug development, encompassing biologics and small molecules. He brings over six years of regulatory experience at the U.S. FDA. He has over 20 years of experience, including experience overseeing clinical operations at Samsung Bioepis.